NASDAQ:JSPR Jasper Therapeutics Q4 2024 Earnings Results & Report $0.50 +0.01 (+1.09%) Closing price 10/14/2026 04:00 PM EasternExtended Trading$0.50 -0.01 (-1.00%) As of 10/14/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Jasper Therapeutics missed analyst earnings expectations in its Q4 2024 results, released February 27, 2025. The company reported EPS of -$1.62 versus the -$1.27 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2024Report DateFebruary 27, 2025TimeBefore Market OpensConference Call8:00 AM ET Jasper Therapeutics EPS ResultsActual EPS-$1.62Consensus EPS -$1.27Beat/MissMissed by -$0.35One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersJasper Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsJasper Therapeutics' Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Jasper Therapeutics Q4 2024 Earnings FAQ Did Jasper Therapeutics beat earnings estimates for Q4 2024? Jasper Therapeutics (NASDAQ:JSPR) reported earnings of -$1.62 per share for Q4 2024, missing the consensus estimate of -$1.27. The report was announced on Thursday, February 27, 2025. When is Jasper Therapeutics' next earnings date? Jasper Therapeutics' next earnings date is estimated for Monday, November 9, 2026. MarketBeat tracks confirmed and estimated earnings dates for Jasper Therapeutics on the company's earnings history page. Jasper Therapeutics Earnings HeadlinesJasper Therapeutics, Inc. (NASDAQ:JSPR) Stock Has Consensus Target Price of $7.33 According to AnalystsOctober 13 at 4:46 AM | americanbankingnews.comJasper Therapeutics (NASDAQ:JSPR) Stock Price Down 2.7% - Here's What HappenedOctober 13 at 1:43 AM | americanbankingnews.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions. | Weiss Ratings (Ad)Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding WarrantsOctober 7, 2026 | globenewswire.comJasper Therapeutics Stockholders Approve Capital Structure FlexibilityOctober 5, 2026 | tipranks.comJasper Therapeutics Announces Key Regulatory and Clinical AppointmentsSeptember 15, 2026 | globenewswire.comSee More Jasper Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Jasper Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Jasper Therapeutics and other key companies, straight to your email. Email Address About Jasper TherapeuticsJasper Therapeutics (NASDAQ:JSPR) is a clinical-stage biotechnology company focused on developing antibody-based therapies for diseases involving the hematopoietic system, including conditions that require the replacement or modification of blood-forming stem cells. The company’s approach is designed to address biological barriers that can limit stem-cell transplantation, gene therapy and the treatment of mast cell–driven diseases. Jasper’s lead product candidate is briquilimab, formerly known as JSP191, an investigational monoclonal antibody that targets CD117, a receptor found on hematopoietic stem cells and mast cells. By blocking CD117, briquilimab is intended to reduce or remove existing stem cells and mast cells, potentially creating space for transplanted or genetically modified cells while reducing the need for intensive chemotherapy-based conditioning. The company has evaluated briquilimab in clinical programs involving hematopoietic stem-cell transplantation and gene therapy, as well as diseases associated with abnormal mast-cell activity, including chronic urticaria. Jasper Therapeutics is headquartered in Redwood City, California, and conducts development activities through clinical studies and collaborations in the United States and other regions. Its products remain investigational and have not been established as approved therapies based on the company’s publicly described pipeline.View Jasper Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
